Literature DB >> 9627136

Immunomodulation of Chiclero's ulcer. Role of eosinophils, T cells, tumour necrosis factor and interleukin-2.

C M Lezama-Dávila1, A P Isaac-Márquez, J Padierna-Olivos, F Aguilar-Torrentera, R Chapa-Ruiz.   

Abstract

The progression of cutaneous leishmaniasis is controlled largely by cell-mediated immunity. Two subpopulations of CD4+ T cells exist that control healing or immunopathology of murine and, perhaps, human leishmaniasis. To better understand the immunological pathways controlling outcome of the human disease, we analysed the pattern of tumour necrosis factor (TNF) and interleukin-2 (IL-2), both of which were present in the sera of humans with active or healed chiclero's ulcer, in relation to the development of delayed-type hypersensitivity (DTH) responses and leucocyte counts in peripheral blood. Increased serum levels of IL-2 and TNF-alpha were apparent only in individuals with active lesions. All individuals with localized cutaneous leishmaniasis developed a strong DTH. The number of T cells was lower in the blood of diseased individuals and the CD4/CD8 ratio was reduced (from 1.5 to 1.0) when compared with the control group. However, diseased and recently cured individuals developed eosinophilia. We conclude that important alterations of the immune response exists in humans suffering from this normally self-healing infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627136     DOI: 10.1046/j.1365-3083.1998.00328.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Systemic cytokine response in humans with chiclero's ulcers.

Authors:  C M Lezama-Davila; A P Isaac-Marquez
Journal:  Parasitol Res       Date:  2006-04-22       Impact factor: 2.289

2.  In Vitro and In Vivo Control of Secondary Bacterial Infection Caused by Leishmania major.

Authors:  Hany M Yehia; Ebtesam M Al-Olayan; Manal F El-Khadragy; Dina M Metwally
Journal:  Int J Environ Res Public Health       Date:  2017-07-13       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.